Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.

Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...

Ozempic (semaglutide) and Victoza (liraglutide) are prescription drugs used to treat type 2 diabetes and reduce the risk of cardiovascular problems. Both drugs come as an injection. Ozempic and ...

Ozempic (semaglutide) and Wegovy (semaglutide) are prescription drugs that may be used to help with long-term weight loss. But only Wegovy is FDA-approved for this use. Both drugs are approved for ...

Semaglutide, a weight-loss drug, can reduce knee pain Arthritis patients, in a study, showed improved physicl activity However, weight loss with lifestyle changes is key for sustained health benefits ...

SANTA MONICA, Calif., October 31, 2024--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). Two separate phase 3 trials show that semaglutide improved fatty ...

A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

In the phase 3 Essence trial, a once-weekly dose of semaglutide 2.4 mg helped to improve liver fibrosis with no worsening of steatohepatitis and to resolve steatohepatitis with no worsening of ...

Part 1 of the trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.

Compared with placebo, once-weekly semaglutide significantly reduced body weight, knee osteoarthritis-related pain, and improved physical function. Topline results were announced from a phase 3 ...